Safety Aspects of Infliximab in Inflammatory Bowel Disease Patients

Publisher： Karger

E-ISSN： 1421-9867|70|1|3-9

ISSN： 0012-2823

Source： Digestion, Vol.70, Iss.1, 2004-09, pp. : 3-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety of Infliximab in Patients Suffering from Inflammatory Bowel Disease

By  

Digestion, Vol. 70, Iss. 1, 2004-09 ,pp. : 1-2

Karger

Access to resources Recommend Favorite

Perceptions of medication safety among patients with inflammatory bowel disease

By Cullen Garret   Donnellan Fergal   Long Syapiq   Forry Mary   Murray Frank E.  

Scandinavian Journal of Gastroenterology, Vol. 45, Iss. 9, 2010-09 ,pp. : 1076-1083

Informa Healthcare

Access to resources Recommend Favorite

Psychological aspects of inflammatory bowel disease

By Hisamatsu Tadakazu   Inoue Nagamu   Yajima Tomoharu   Izumiya Motoko   Ichikawa Hitoshi   Hibi Toshifumi  

Journal of Gastroenterology, Vol. 42, Iss. 17, 2007-01 ,pp. : 34-40

Springer Publishing Company

Access to resources Recommend Favorite

Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study

By Steenholdt Casper   Molazahi Akbar   Ainsworth Mark Andrew   Brynskov Jørn   Thomsen Ole Østergaard   Seidelin Jakob Benedict  

Scandinavian Journal of Gastroenterology, Vol. 47, Iss. 5, 2012-05 ,pp. : 518-527

Informa Healthcare

Access to resources Recommend Favorite

Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre

By  

Digestive Diseases, Vol. 35, Iss. 1-2, 2017-02 ,pp. : 91-100

Karger

Access to resources Recommend Favorite